MDACC Study No:2012-0062 ( NCT No: NCT01546038)
Title:A Phase 1B/2 Study to Evaluate the Safety and Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose Ara-C or Decitabine in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Principal Investigator:Jorge Cortes
Treatment Agent:Cytarabine; Daunorubicin; PF-04449913
Study Status:Closed
Study Description:The goal of Part 1 of this clinical research study is to learn the highest
tolerable dose of PF-04449913 that can be given with cytarabine or decitabine
to patients with AML or high-risk MDS. The goal of Part 2 (Expansion) is to
learn if the study drug combinations can help to control the disease.

PF-04449913 is designed to stop the growth of certain cancer stem cells that
may allow cancer to grow.

Cytarabine is designed to insert itself into DNA (genetic material) of cancer
cells and stop the DNA from repairing itself.

Decitabine is designed to damage the DNA of cells, which may cause cancer cells
to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:Cytarabine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Pfizer, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults